{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:15:35Z","timestamp":1740125735925,"version":"3.37.3"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1111\/ecc.12800","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T21:13:49Z","timestamp":1515532429000},"page":"e12800","source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study"],"prefix":"10.1155","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-6611","authenticated-orcid":false,"given":"J.J.","family":"Koldenhof","sequence":"first","affiliation":[{"name":"Department of Medical Oncology; Cancer Center; University Medical Center Utrecht; Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.G.","family":"Langenberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Cancer Center; University Medical Center Utrecht; Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.O.","family":"Witteveen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Cancer Center; University Medical Center Utrecht; Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.C.M.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Department of Primary Care; Julius Center for Health Sciences and Primary Care; University Medical Center Utrecht; Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"10.1111\/ecc.12800-BIB0001|ecc12800-cit-0001","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1111\/ecc.12800-BIB0002|ecc12800-cit-0002","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"The American Statistician"},{"key":"10.1111\/ecc.12800-BIB0003|ecc12800-cit-0003","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2010-0063","article-title":"Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: An early and a late phase of papulopustular eruptions","volume":"15","author":"Amitay-Laish","year":"2010","journal-title":"Oncologist"},{"key":"10.1111\/ecc.12800-BIB0004|ecc12800-cit-0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/156800906779010191","article-title":"EGFR-targeting monoclonal antibodies in head and neck cancer","volume":"6","author":"Astsaturov","year":"2006","journal-title":"Current Cancer Drug Targets"},{"key":"10.1111\/ecc.12800-BIB0005|ecc12800-cit-0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12800-BIB0006|ecc12800-cit-0006","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1037\/1082-989X.7.3.370","article-title":"Statistical inference for a linear function of medians: Confidence intervals, hypothesis testing, and sample size requirements","volume":"7","author":"Bonett","year":"2002","journal-title":"Psychological Methods"},{"key":"10.1111\/ecc.12800-BIB0007|ecc12800-cit-0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1111\/ecc.12800-BIB0008|ecc12800-cit-0008","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1111\/ecc.12800-BIB0009|ecc12800-cit-0009","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: A five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12800-BIB0010|ecc12800-cit-0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"Journal of Palliative Care"},{"key":"10.1111\/ecc.12800-BIB0011|ecc12800-cit-0011","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3892\/ol.2013.1301","article-title":"Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis","volume":"5","author":"Chen","year":"2013","journal-title":"Oncology Letters"},{"key":"10.1111\/ecc.12800-BIB0012|ecc12800-cit-0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/B:QURE.0000018499.64574.1f","article-title":"Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?","volume":"13","author":"Boer","year":"2004","journal-title":"Quality of Life Research"},{"issue":"23","key":"10.1111\/ecc.12800-BIB0500|ecc12800-cit-0500","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1001\/jama.288.23.3027","article-title":"Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial","volume":"288","author":"Detmar","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/ecc.12800-BIB0013|ecc12800-cit-0013","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2010.03.008","article-title":"Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study","volume":"46","author":"Duffour","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1111\/ecc.12800-BIB0014|ecc12800-cit-0014","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/ecc.12800-BIB0015|ecc12800-cit-0015","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.ejca.2014.08.008","article-title":"A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer","volume":"50","author":"Hickish","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1111\/ecc.12800-BIB0501|ecc12800-cit-0501","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton Symptom Assessment System 25 Years Later: Past, Present and Future Developments","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Management"},{"key":"10.1111\/ecc.12800-BIB0016|ecc12800-cit-0016","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1111\/ecc.12800-BIB0017|ecc12800-cit-0017","first-page":"2371","article-title":"Symptoms from treatment with sunitinib or sorafenib: A multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions","volume":"22","author":"Koldenhof","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/ecc.12800-BIB0018|ecc12800-cit-0018","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jrr\/rrv038","article-title":"Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients","volume":"56","author":"Kurokawa","year":"2015","journal-title":"Journal of Radiation Research"},{"key":"10.1111\/ecc.12800-BIB0019|ecc12800-cit-0019","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000365994","article-title":"The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors","volume":"87","author":"Lisi","year":"2014","journal-title":"Oncology"},{"key":"10.1111\/ecc.12800-BIB0020|ecc12800-cit-0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0885-3924(95)00059-8","article-title":"Nurses\u2019 knowledge about cancer pain: A survey of five countries","volume":"10","author":"McCaffery","year":"1995","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1111\/ecc.12800-BIB0021|ecc12800-cit-0021","first-page":"742","article-title":"The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck","volume":"6","author":"Mehra","year":"2008","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"10.1111\/ecc.12800-BIB0022|ecc12800-cit-0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"10.1111\/ecc.12800-BIB0024|ecc12800-cit-0024","unstructured":"National Cancer Institute 2009 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0."},{"key":"10.1111\/ecc.12800-BIB0026|ecc12800-cit-0026","doi-asserted-by":"crossref","unstructured":"Pfeiffer , P. Sorbye , H. Qvortrup , C. Karlberg , M. Kersten , C. Vistisen , K. Glimelius , B. 2015 Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: The NORDIC-7.5 study by the Nordic Colorectal Cancer Biomodulation Group","DOI":"10.1016\/j.clcc.2015.03.002"},{"key":"10.1111\/ecc.12800-BIB0027|ecc12800-cit-0027","first-page":"55","article-title":"A review of the reliability and validity of the Edmonton Symptom Assessment System","volume":"16","author":"Richardson","year":"2009","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"10.1111\/ecc.12800-BIB0028|ecc12800-cit-0028","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12800-BIB0029|ecc12800-cit-0029","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12800-BIB0030|ecc12800-cit-0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable cancer: A systematic review","volume":"34","author":"Teunissen","year":"2007","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1111\/ecc.12800-BIB0031|ecc12800-cit-0031","first-page":"945","article-title":"Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors","volume":"151","author":"Tjin-A-Ton","year":"2007","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1111\/ecc.12800-BIB0032|ecc12800-cit-0032","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1111\/ecc.12800-BIB0033|ecc12800-cit-0033","first-page":"289","article-title":"Treatment of skin toxicities with targeted agents in oncology","volume":"22","author":"Van Dalen","year":"2012","journal-title":"Nederlands Tijdschrift voor Dermatologie en Venereologie"},{"issue":"6","key":"10.1111\/ecc.12800-BIB0502|ecc12800-cit-0502","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/cncr.29104","article-title":"Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care","volume":"121","author":"Wagner","year":"2015","journal-title":"Cancer"},{"key":"10.1111\/ecc.12800-BIB0034|ecc12800-cit-0034","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","article-title":"A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition","volume":"17","author":"Wollenberg","year":"2008","journal-title":"Experimental Dermatology"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12800\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:11:16Z","timestamp":1671541876000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12800","archive":["Portico"],"relation":{},"ISSN":["0961-5423"],"issn-type":[{"type":"print","value":"0961-5423"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}